154 related articles for article (PubMed ID: 7538815)
1. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
D'Hondt V; Humblet Y; Guillaume T; Baatout S; Chatelain C; Berlière M; Longueville J; Feyens AM; de Greve J; Van Oosterom A
Blood; 1995 May; 85(9):2347-53. PubMed ID: 7537110
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates.
Zeidler C; Kanz L; Hurkuck F; Rittmann KL; Wildfang I; Kadoya T; Mikayama T; Souza L; Welte K
Blood; 1992 Dec; 80(11):2740-5. PubMed ID: 1280477
[TBL] [Abstract][Full Text] [Related]
4. Effects of rhIL-11 on normal dogs and after sublethal radiation.
Nash RA; Seidel K; Storb R; Slichter S; Schuening FG; Appelbaum FR; Becker AB; Bolles L; Deeg HJ; Graham T
Exp Hematol; 1995 May; 23(5):389-96. PubMed ID: 7720811
[TBL] [Abstract][Full Text] [Related]
5. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW
Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886
[TBL] [Abstract][Full Text] [Related]
7. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
Leonard JP; Neben TY; Kozitza MK; Quinto CM; Goldman SJ
Exp Hematol; 1996 Feb; 24(2):270-6. PubMed ID: 8641352
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
[TBL] [Abstract][Full Text] [Related]
10. Potential use of recombinant human interleukin-6 in clinical oncology.
Veldhuis GJ; Willemse PH; Mulder NH; Limburg PC; De Vries EG
Leuk Lymphoma; 1996 Feb; 20(5-6):373-9. PubMed ID: 8833392
[TBL] [Abstract][Full Text] [Related]
11. Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
Keever-Taylor CA; Witt PL; Truitt RL; Ramanujam S; Borden EC; Ritch PS
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):231-43. PubMed ID: 8811498
[TBL] [Abstract][Full Text] [Related]
12. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
Hofmann WK; Kalina U; Wagner S; Seipelt G; Ries C; Hoelzer D; Ottmann OG
Exp Hematol; 1999 Mar; 27(3):395-400. PubMed ID: 10089900
[TBL] [Abstract][Full Text] [Related]
13. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes.
Nand S; Sosman J; Godwin JE; Fisher RI
Blood; 1994 Jan; 83(2):357-60. PubMed ID: 8286736
[TBL] [Abstract][Full Text] [Related]
15. Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin-6.
Yonemura Y; Kawakita M; Masuda T; Fujimoto K; Takatsuki K
Br J Haematol; 1993 May; 84(1):16-23. PubMed ID: 8338768
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.
Ganser A; Seipelt G; Lindemann A; Ottmann OG; Falk S; Eder M; Herrmann F; Becher R; Höffken K; Büchner T
Blood; 1990 Aug; 76(3):455-62. PubMed ID: 2378979
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of thrombopoiesis in mice by fibroblast growth factor 9.
Matsumoto-Yoshitomi S; Seko C; Kuroshima K; Naruo K; Shino A; Kondo T; Kurokawa T
Growth Factors; 1995; 12(3):179-90. PubMed ID: 8619924
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial.
Negrin RS; Haeuber DH; Nagler A; Olds LC; Donlon T; Souza LM; Greenberg PL
Ann Intern Med; 1989 Jun; 110(12):976-84. PubMed ID: 2471429
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia.
Schrezenmeier H; Marsh JC; Stromeyer P; Müller H; Heimpel H; Gordon-Smith EC; Raghavachar A
Br J Haematol; 1995 Jun; 90(2):283-92. PubMed ID: 7794747
[TBL] [Abstract][Full Text] [Related]
20. Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis.
Carrington PA; Hill RJ; Stenberg PE; Levin J; Corash L; Schreurs J; Baker G; Levin FC
Blood; 1991 Jan; 77(1):34-41. PubMed ID: 1984801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
